Corindus Vascular Robotics Inc
Corindus Vascular Robotics — Investor Presentation (November 2014)
23 slides from Corindus Vascular Robotics's investor presentation, Nov 19, 2014
Slide 1: Precision Vascular Robotics Corindus Overview November 2014
Precision Vascular Robotics Corindus Overview November, 2014 1
Slide 2: Forward Looking Statements
FORWARD LOOKING STATEMENTS THIS PRESENTATION CONTAINS “FORWARD - LOOKING STATEMENTS” (AS SUCH TERM IS DEFINED IN SECTION 27 A OF THE SECURITIES ACT OF 1933 , AS AMENDED, AND SECTION 21 E OF THE SECURITIES EXCHANGE ACT OF 1934 , AS AMENDED, AND INFORMATION RELATING TO THE COMPANY, THAT ARE BASED ON T
Slide 3: Corindus Overview: The leader in precision vascular robotics
3 Corindus Overview The leader in precision vascular robotics Overview • Only FDA cleared robotic - assisted percutaneous coronary intervention (“PCI”) system • Large US market : 940,000 PCI procedures; 3,250 labs • Provides strong clinical and economic value proposition for patient, hospital and ph
Slide 4: CorPath Robotic PCI: Largest Cath Lab Procedure Innovation
2014 CorPath Robotic PCI Largest Cath Lab Procedure Innovation CorPath Robotic - assisted PCI 1986 First Stent Procedure 2013 Procedure Unchanged >> 4 PCI procedure remains largely unchanged since introduction • Innovation historically focused on stents and delivery systems • PCI not optimized to re
Slide 5: Vascular Robotics Market
Vascular Robotics Market CorPath platform potential to expand vascular indications Peripheral (1.5M Procedures) Coronary Peripheral Neuro Structural Corindus IP and Technology 5
Slide 6: Corindus Market Opportunity
Corindus Market Opportunity FY2018 market estimate 2 6 • New System Sales annual opportunity based on 5 - year replacement cycle in 5,750 US labs and 7,540 OUS labs, at a blended average price per system of $350,000. Prices vary by procedure type and geography. • Non - PCI procedure types are Periph
Slide 7: Product Overview
Product Overview 7
Slide 8: CorPath Robotic-Assisted PCI System
CorPath Robotic - Assisted PCI System 8
Slide 9: Today's Cath Lab Challenges
Today’s Cath Lab Challenges Staff Safety and Health is at Risk • The cath lab is a dangerous environment for workers » Radiation exposure cancer and cataract risk » Ergonomic Strain orthopedic injury and pain Procedure Outcomes Not Optimal • Difficulty viewing angiography standing at bedside • I
Slide 10: Safety in a Hazardous Environment
• Lab ergonomics create awkward working positions • Lead protection exacerbates stress loading – pressures up to 300 psi on discs propagating “interventionalist disc disease” • Radiation exposure – increased risk of brain tumor, leukemia/lymphoma, cataracts Safety in a Hazardous Environment Reduce r
Slide 11: Traditional PCI vs. CorPath Robotic PCI
Enhanced procedure may i mprove outcomes , economics and safety Traditional PCI vs. CorPath ® Robotic PCI 11 Struggle to see angiography Assess Anatomy Close proximity ergonomic visualization Trial & error, wire spinning Navigate Precise ‘Point & Shoot’ predictability ‘Eyeball’ estimate Measure Anat
Slide 12: Precision Matters in PCI: STLLR Trial
Stent Deployment Procedural Factors – STLLR Trial • 1,557 patients, 41 US hospitals • Published Journal American College of Cardiology 1 Longitudinal Geographic Miss (LGM) • Independent Core Lab identified LGM • 47.6 % * of patients had LGM stent placements 12 STLLR Trial patients evaluated for LGM
Slide 13: Inaccurate Lesion Assessment
Inaccurate Lesion Assessment Visual estimation impacts proper stent selection • >65% physicians select stent length based on visual estimation alone 1 – Physician visual estimation is inconsistent 2 • Inaccurate estimates lead to sub - optimal PCI procedure 13 1 65% according to an online survey, Ju
Slide 14: PRECISE vs. Historical Data
1 Nikolsky E, Pucelikova T, Mehran R, et al. An Evaluation of fluoroscopy time and correlation with outcomes after percutaneous coronary intervention. J Invasive Cardiol, 2007, 19: 208 - 213 2 Weisz G, et al. Safety and Feasibility of Robotic Percutaneous Coronary Intervention. J American College of
Slide 15: Clinical Evidence – Precision Matters
15 Clinical Evidence – Precision Matters Peer reviewed publication highlights Continued Investment in Clinical Data • Post PRECISE sub - analysis • PRECISION registry post market data collection and analysis vs. manual procedures • Concurrent studies to prove procedure benefits of CorPath robotic pr
Slide 16: Commercial Strategy
Commercial Strategy 16
Slide 17: Sales Strategy
Sales Strategy Dedicated system and cassette sales teams 17 System Sales Team • Experienced medical technology sales professionals – System ‘hunters’ • Leveraging both capital and usage models to accelerate sales • Increasing field team • Focused on largest market areas Cassette Sales Team • Experie
Slide 18: Intellectual Property
Intellectual Property 18
Slide 19: Intellectual Property Overview
Intellectual Property Overview Expanding on a strong f oundation Continuous “Ring - fencing” all vascular robotics applications: • 30 issued global patents • 54 patents pending: broad application coverage • Continuously building IP portfolio • Pursuing the entire vascular space 19 The only company a
Slide 20: Corindus Vascular Robotics
Corindus Vascular Robotics
Slide 21: Key Financial Information
Key Financial Information 21 Key Metrics* Cash, Cash Equivalents and Marketable Securities $6.9 million Private Placements in Q3 2014 $27.5 million Debt** $5.0 million Basic Weighted Average Shares Outstanding 73,360,273 Warrants Outstanding 5,029,865 Stock Options Outstanding 9,046,549 Closing Shar
Slide 22: Corindus Growth Platform
• PCI is a very large volume medical robotics procedure opportunity; long growth runway • Established initial installed base during 2013 limited launch • PCI commercial foundation and regional show sites in place • Sales team expansion and funnel building across US • Building technology and clinical
Slide 23: About Corindus
Precision Vascular Robotics The New Standard of Care in Vascular Procedures 23 About Corindus Vascular Robotics Corindus Vascular Robotics is a global technology leader in robotic - assisted percutaneous coronary interventions. The company’s CorPath System is the first medical device that offers int
Corindus Vascular Robotics — Investor Presentation (November 2014) on 6ix